Nascent Biotech, Inc.
NBIO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.38 | -0.10 | 0.45 |
| FCF Yield | 0.00% | -2.14% | -1.15% | -1.14% |
| EV / EBITDA | -32.40 | -40.47 | -59.42 | -78.06 |
| Quality | ||||
| ROIC | 35.62% | 82.47% | 384.58% | -235.16% |
| Gross Margin | 0.00% | 0.00% | -5,361,374.41% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.69 | 1.61 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | -98.50% | -98.50% | -98.50% | -100.00% |
| Free Cash Flow Growth | 0.00% | 7.68% | -6.55% | 3.34% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | -0.03 | 0.49 | 1.37 |
| Interest Coverage | -228.18 | -192.45 | 206.40 | -14.64 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -536.21 | -340.66 | 0.00 |